Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

ABC News chief medical correspondent Dr. Tara Narula breaks down what to know about a new study that says Zepbound may be ...

Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.

Zepbound targets two hormones (GLP-1 and GIP), while Wegovy targets only GLP-1, AP reported. "Two drugs together can produce better weight loss," said lead study author Dr. Louis Aronne of Weill ...